Fennec Pharmaceuticals Reports Strong 2024 Financials and Expands Global Reach

An update from Fennec Pharmaceuticals ( (TSE:FRX) ) is now available.

Fennec Pharmaceuticals reported a 40% increase in full-year net product sales for 2024, driven by the adoption of PEDMARK in the adolescent and young adult segment and its commercial launch in the UK and Germany. The company also completed an early repayment of $13 million of its convertible debt, optimizing its balance sheet and saving on future interest payments. With ongoing clinical trials in Japan and strategic partnerships in Turkey and the Gulf Cooperation Council countries, Fennec is poised for further international expansion. These developments are expected to enhance shareholder value and solidify the company’s position in the pharmaceutical industry.

More about Fennec Pharmaceuticals

Fennec Pharmaceuticals Inc. is a specialty pharmaceutical company focused on developing and commercializing products for the treatment of cancer-related conditions. The company’s primary product, PEDMARK, is aimed at preventing ototoxicity in cancer patients, with a market focus on expanding access and adoption in both the U.S. and international markets.

YTD Price Performance: 9.38%

Average Trading Volume: 60,628

Technical Sentiment Consensus Rating: Sell

Current Market Cap: $187.4M

Learn more about FRX stock on TipRanks’ Stock Analysis page.